The Peroxisome Proliferator-Activated Receptor-γ Agonist Pioglitazone Represses Inflammation in a Peroxisome Proliferator-Activated Receptor-α–Dependent Manner In Vitro and In Vivo in Mice
- 2 September 2008
- journal article
- clinical trial
- Published by Elsevier BV in Journal of the American College of Cardiology
- Vol. 52 (10), 869-881
- https://doi.org/10.1016/j.jacc.2008.04.055
Abstract
No abstract availableKeywords
This publication has 93 references indexed in Scilit:
- Pioglitazone and Risk of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Meta-analysis of Randomized TrialsYearbook of Endocrinology, 2008
- Cardiovascular safety of rosiglitazoneThe Lancet, 2007
- Safety Considerations with Fibrate TherapyThe American Journal of Cardiology, 2007
- Parallel SUMOylation-Dependent Pathways Mediate Gene- and Signal-Specific Transrepression by LXRs and PPARγMolecular Cell, 2007
- Hydrogen/deuterium‐exchange (H/D‐Ex) of PPARγ LBD in the presence of various modulatorsProtein Science, 2006
- Insulin resistance and atherosclerosisJCI Insight, 2006
- A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γNature, 2005
- Elevated Soluble Cellular Adhesion Molecules in Subjects With Low HDL-CholesterolArteriosclerosis, Thrombosis, and Vascular Biology, 2002
- Clinical pharmacokinetics of pioglitazoneExperimental and Clinical Endocrinology & Diabetes, 2000
- Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by PioglitazoneBiochemical and Biophysical Research Communications, 2000